title: Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel.
abstract: Statins are one of the most commonly prescribed drugs in clinical practice. They are usually well tolerated and effectively prevent cardiovascular events. Most adverse effects associated with statin therapy are muscle-related. The recent statement of the European Atherosclerosis Society (EAS) has focused on statin-associated muscle symptoms (SAMS), and avoided the use of the term 'statin intolerance'. Although muscle syndromes are the most common adverse effects observed after statin therapy, excluding other side effects might underestimate the number of patients with statin intolerance, which might be observed in 10 - 15% of patients. In clinical practice, statin intolerance limits effective treatment of patients at risk of, or with, cardiovascular disease. Knowledge of the most common adverse effects of statin therapy that might cause statin intolerance and the clear definition of this phenomenon is crucial to effectively treat patients with lipid disorders. Therefore, the aim of this position paper was to suggest a unified definition of statin intolerance, and to complement the recent EAS statement on SAMS, where the pathophysiology, diagnosis and the management were comprehensively presented.
authors.affiliation: Medical University of Lodz, Department of Hypertension, Chair of Nephrology and Hypertension , Zeromskiego 113; 90-549 Lodz , Poland +48 42 639 37 71 ; +48 42 639 37 71 ; maciejbanach@aol.co.uk.
authors.forename: Maciej
authors.initials: M
authors.lastname: Banach
authors.forename: Manfredi
authors.initials: M
authors.lastname: Rizzo
authors.forename: Peter P
authors.initials: PP
authors.lastname: Toth
authors.forename: Michel
authors.initials: M
authors.lastname: Farnier
authors.forename: Michael H
authors.initials: MH
authors.lastname: Davidson
authors.forename: Khalid
authors.initials: K
authors.lastname: Al-Rasadi
authors.forename: Wilbert S
authors.initials: WS
authors.lastname: Aronow
authors.forename: Vasilis
authors.initials: V
authors.lastname: Athyros
authors.forename: Dragan M
authors.initials: DM
authors.lastname: Djuric
authors.forename: Marat V
authors.initials: MV
authors.lastname: Ezhov
authors.forename: Robert S
authors.initials: RS
authors.lastname: Greenfield
authors.forename: G Kees
authors.initials: GK
authors.lastname: Hovingh
authors.forename: Karam
authors.initials: K
authors.lastname: Kostner
authors.forename: Corina
authors.initials: C
authors.lastname: Serban
authors.forename: Daniel
authors.initials: D
authors.lastname: Lighezan
authors.forename: Zlatko
authors.initials: Z
authors.lastname: Fras
authors.forename: Patrick M
authors.initials: PM
authors.lastname: Moriarty
authors.forename: Paul
authors.initials: P
authors.lastname: Muntner
authors.forename: Assen
authors.initials: A
authors.lastname: Goudev
authors.forename: Richard
authors.initials: R
authors.lastname: Ceska
authors.forename: Stephen J
authors.initials: SJ
authors.lastname: Nicholls
authors.forename: Marlena
authors.initials: M
authors.lastname: Broncel
authors.forename: Dragana
authors.initials: D
authors.lastname: Nikolic
authors.forename: Daniel
authors.initials: D
authors.lastname: Pella
authors.forename: Raman
authors.initials: R
authors.lastname: Puri
authors.forename: Jacek
authors.initials: J
authors.lastname: Rysz
authors.forename: Nathan D
authors.initials: ND
authors.lastname: Wong
authors.forename: Laszlo
authors.initials: L
authors.lastname: Bajnok
authors.forename: Steven R
authors.initials: SR
authors.lastname: Jones
authors.forename: Kausik K
authors.initials: KK
authors.lastname: Ray
authors.forename: Dimitri P
authors.initials: DP
authors.lastname: Mikhailidis
mesh_terms: D002318:Cardiovascular Diseases / Q000517:prevention & control; D050171:Dyslipidemias / Q000188:drug therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D009135:Muscular Diseases / Q000139:chemically induced* / Q000453:epidemiology
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords: definition; muscle symptoms; risk factors; statin intolerance